Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1621

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7
Chunk 1621
---

    $640,830  
    $640,830 
  
    Total 
    $-  
    $-  
    $640,830  
    $640,830 

    December 31, 2023 

    Level 1  
    Level 2  
    Level 3  
    Total 
  
    Liabilities: 

    Derivative Liabilities 
    $          -  
    $         -  
    $2,306,796  
    $2,306,796 
  
    Total 
    $-  
    $-  
    $2,306,796  
    $2,306,796 

There were no transfers of financial instruments
between Level 1, Level 2, and Level 3 during the periods presented. However, certain liabilities measured at fair value and using Level
3 inputs were extinguished during the year ended December 31, 2023. A rollforward of liabilities measured at fair value using Level 3
inputs outstanding during the years ended December 31, 2024 and 2023 are presented in Notes 7 (Debt) and 8 (Derivative Liabilities).

Assets and Liabilities Not Measured at Fair Value on a Recurring
Basis

In addition to assets and liabilities that are
measured at fair value on a recurring basis, the Company also measures certain assets and liabilities at fair value on a nonrecurring
basis. The Company’s non-financial assets, including Intangible Assets and Property and Equipment, are measured at fair value when
there is an indication of impairment and the carrying amount exceeds the asset’s projected undiscounted cash flows. These assets
are recorded at fair value only when an impairment charge is recognized. 

As of December 31, 2024 and 2023, the carrying
value of the Company’s financial instruments included in current assets and current liabilities (such as cash, accounts receivable,
accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments. Certificates of
deposit, classified as cash equivalents or short-term investments depending on the instrument’s original time to maturity, are
measured at amortized cost, which approximates fair value as of December 31, 2024. The Company did not have any investments in certificates
of deposit as of December 31, 2023. 

Foreign Currency Transactions and Translation

The